论文部分内容阅读
目的探讨贝那普利联合胺碘酮治疗阵发性心房颤动患者的临床效果。方法回顾性分析2013年1月至2014年4月大连市第三人民医院收治的阵发性心房颤动患者124例,根据随机数字表法将其分为观察组和对照组,各62例。对照组患者口服胺碘酮,观察组患者在对照组基础上口服贝那普利,比较两组患者左心室射血分数(EF)、左心室内径缩短率(FS)、左心室收缩末期内径(LVESd)、B型钠尿肽(BNP)、窦性心律转复率、不良反应发生情况及治疗前后心内径。结果治疗后,观察组患者BNP、LVESd均明显低于对照组,EF、FS均明显高于对照组,差异均有统计学意义(均P<0.05);治疗后12个月,观察组患者心内径为(34±1.3)mm,明显低于对照组的(37.3±1.4)mm,差异有统计学意义(P<0.05);治疗后1、3、6、12个月观察组患者的窦性心律转复率均明显高于对照组,差异均有统计学意义(均P<0.05);观察组患者不良反应发生率明显低于对照组,差异有统计学意义(P<0.05)。结论贝那普利联合胺碘酮治疗阵发性心房颤动临床疗效明显,有利于改善患者预后,具有较高的可行性和安全性。
Objective To investigate the clinical effect of benazepril combined with amiodarone in patients with paroxysmal atrial fibrillation. Methods 124 patients with paroxysmal atrial fibrillation admitted to the Third People’s Hospital of Dalian from January 2013 to April 2014 were retrospectively analyzed. According to the random number table, they were divided into observation group and control group, with 62 cases in each group. The patients in the control group were treated with oral amiodarone orally and the patients in the observation group were given oral benazepril on the basis of the control group. The left ventricular ejection fraction (EF), left ventricular diameter shortening (FS), end-systolic diameter LVESd), type B natriuretic peptide (BNP), sinus rhythm recovery, adverse reactions and heart diameter before and after treatment. Results After treatment, BNP and LVESd in observation group were significantly lower than those in control group, and EF and FS were significantly higher than those in control group (all P <0.05). At 12 months after treatment, The internal diameter was (34 ± 1.3) mm, which was significantly lower than that of the control group (37.3 ± 1.4) mm, the difference was statistically significant (P <0.05). The sinusoids The rate of heart rate recovery was significantly higher than that of the control group (all P <0.05). The incidence of adverse reactions in the observation group was significantly lower than that in the control group (P <0.05). Conclusion The combination of benazepril and amiodarone in the treatment of paroxysmal atrial fibrillation has obvious curative effect, which is beneficial to improve the prognosis of patients with high feasibility and safety.